BRPI0921802A2 - combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor - Google Patents

combinação de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor

Info

Publication number: BRPI0921802A2
Authority: BR; Brazil
Prior art keywords: inhibitor; pi3k; phosphatidylinositol; kinase; combination
Prior art date: 2008-10-31

Application number

BRPI0921802A

Other languages

English (en)

Inventor

Carlos Garcia-Echeverria

Sauveur-Michel Maira

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2008-10-31

Filing date

2009-10-29

Publication date

2016-09-27

2009-10-29 Application filed by Novartis Ag filed Critical Novartis Ag

2016-09-27 Publication of BRPI0921802A2 publication Critical patent/BRPI0921802A2/pt

2018-03-13 Publication of BRPI0921802A8 publication Critical patent/BRPI0921802A8/pt

Links

229940124302 mTOR inhibitor Drugs 0.000 title 1
239000003628 mammalian target of rapamycin inhibitor Substances 0.000 title 1
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Neurology (AREA)
Cardiology (AREA)
Epidemiology (AREA)
Heart & Thoracic Surgery (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Immunology (AREA)
Oncology (AREA)
Physical Education & Sports Medicine (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Virology (AREA)
Ophthalmology & Optometry (AREA)
Pulmonology (AREA)
Hematology (AREA)
Vascular Medicine (AREA)
Rheumatology (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

BRPI0921802A 2008-10-31 2009-10-29 uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo. BRPI0921802A8 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP08168044		2008-10-31
PCT/EP2009/064274 WO2010049481A1 (en)	2008-10-31	2009-10-29	Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor

Publications (2)

Publication Number	Publication Date
BRPI0921802A2 true BRPI0921802A2 (pt)	2016-09-27
BRPI0921802A8 BRPI0921802A8 (pt)	2018-03-13

Family

ID=40332588

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0921802A BRPI0921802A8 (pt)	2008-10-31	2009-10-29	uso de um inibidor de fosfatidilinositol-3-cinase (pi3k) e um inibidor de mtor,bem como composição e combinação farmacêuticas os compreendendo.

Country Status (12)

Country	Link
US (3)	US20110195966A1 (pt)
EP (1)	EP2349275B1 (pt)
JP (4)	JP2012506898A (pt)
KR (1)	KR20110090911A (pt)
CN (2)	CN105030784A (pt)
AU (1)	AU2009309616B2 (pt)
BR (1)	BRPI0921802A8 (pt)
CA (1)	CA2736361C (pt)
ES (1)	ES2627677T3 (pt)
MX (1)	MX2011004585A (pt)
RU (2)	RU2538683C2 (pt)
WO (1)	WO2010049481A1 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20100048524A1 (en)	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US8476431B2 (en) *	2008-11-03	2013-07-02	Itellikine LLC	Benzoxazole kinase inhibitors and methods of use
CA2937492C (en)	2008-11-11	2019-08-13	The Board Of Regents Of The University Of Texas System	Inhibition of mammalian target of rapamycin
EP2393827B1 (en)	2009-02-05	2015-10-07	Tokai Pharmaceuticals, Inc.	Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens
US9283211B1 (en)	2009-11-11	2016-03-15	Rapamycin Holdings, Llc	Oral rapamycin preparation and use for stomatitis
US10391059B2 (en)	2009-11-11	2019-08-27	Rapamycin Holdings, Inc.	Oral rapamycin nanoparticle preparations and use
GB2478556A (en) *	2010-03-09	2011-09-14	Myrovlytis Technology Ventures Ltd	A composition for use in the treatment of Birt-Hogg-Dubô sydrome
CN103391780B (zh) *	2011-02-16	2015-08-19	诺瓦提斯公司	用于治疗神经变性疾病的治疗剂的组合物
TWI592411B (zh) *	2011-02-23	2017-07-21	英特爾立秦有限責任公司	激酶抑制劑之組合及其用途
KR20130131461A (ko) *	2011-03-07	2013-12-03	폰다지오네 텔레톤	Tfeb 변종 및 그의 용도
WO2012148846A1 (en) *	2011-04-25	2012-11-01	Novartis Ag	Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor
JP6047149B2 (ja) *	2011-05-04	2016-12-21	インテリカイン，エルエルシー	併用の医薬組成物およびその使用
MX342326B (es)	2011-09-27	2016-09-26	Novartis Ag	3-pirimidin-4-il-oxazolidin-2-onas como inhibidoras de idh mutante.
CN104080786A (zh) *	2011-11-08	2014-10-01	因特利凯有限责任公司	使用多种药剂的治疗方案
US9174994B2 (en)	2011-11-23	2015-11-03	Intellikine, Llc	Enhanced treatment regimens using mTor inhibitors
UY34632A (es) *	2012-02-24	2013-05-31	Novartis Ag	Compuestos de oxazolidin- 2- ona y usos de los mismos
RU2012112128A (ru) *	2012-03-29	2013-10-10	Холин Максим Николаевич	ИНГИБИТОРЫ СИГНАЛЬНОГО ПУТИ PI3K/AKT/IKK/NF-kB, ИХ ФАРМАЦЕВТИЧЕСКИ ПРИЕМЛЕМЫЕ СОЛИ И СОДЕРЖАЩИЕ ИХ КОМПОЗИЦИИ ДЛЯ ПРОФИЛАКТИКИ И ЛЕЧЕНИЯ ВИРУСНЫХ ЗАБОЛЕВАНИЙ
US9296733B2 (en)	2012-11-12	2016-03-29	Novartis Ag	Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
US20160030401A1 (en)	2013-03-13	2016-02-04	The Board Of Regents Of The University Of Texas System	Use of mtor inhibitors for prevention of intestinal polyp growth and cancer
CA2904170A1 (en)	2013-03-14	2014-09-25	University Of Maryland, Baltimore	Androgen receptor down-regulating agents and uses thereof
CA2903979A1 (en)	2013-03-14	2014-09-18	Novartis Ag	3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
HK1214533A1 (zh)	2013-03-15	2016-07-29	基因泰克公司	治疗癌症和预防癌症耐药性的方法
TWI710558B (zh) *	2013-05-01	2020-11-21	瑞士商赫孚孟拉羅股份公司	二雜芳基化合物及其用途
KR20160058774A (ko)	2013-08-12	2016-05-25	토카이 파마슈티컬, 아이엔씨.	안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
CN103483345B (zh) *	2013-09-25	2016-07-06	中山大学	Pi3k激酶抑制剂、包含其的药物组合物及其应用
US9700544B2 (en)	2013-12-31	2017-07-11	Neal K Vail	Oral rapamycin nanoparticle preparations
EP3283127B1 (en) *	2015-04-15	2020-02-26	University of Massachusetts	Compositions and methods for xi chromosome reactivation
US10576076B2 (en)	2015-05-20	2020-03-03	Novartis Ag	Pharmaceutical combination of everolimus with dactolisib
JP2020500930A (ja)	2016-11-23	2020-01-16	ノバルティスアーゲー	エベロリムス、ダクトリシブまたは両方で免疫応答を増強する方法
WO2019157516A1 (en)	2018-02-12	2019-08-15	resTORbio, Inc.	Combination therapies
KR20210158019A (ko)	2020-06-23	2021-12-30	주식회사 온코빅스	포스파티딜이노시톨 3-키나제(pi3k) 억제제로써 pten 과오종 증후군에 의한 종양 세포의 성장 또는 증식을 억제하는데 유용한 신규한 피리미딘 유도체 및 이의 약제학적으로 허용가능한 염, 및 이를 유효성분으로 함유하는 약제학적 조성물
CN112294967A (zh) *	2020-09-30	2021-02-02	四川大学	一种mTOR抑制剂与抗癌药物的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR100919266B1 (ko) *	2000-06-26	2009-09-30	엔벤타 바이오파마슈티컬스 코포레이션	인간 파필로마 바이러스 치료법
TW200626610A (en) *	2004-10-13	2006-08-01	Wyeth Corp	Analogs of 17-hydroxywortmannin as PI3K inhibitors
CN101222925A (zh) *	2005-07-20	2008-07-16	诺瓦提斯公司	嘧啶基氨基苯甲酰胺和mTOR激酶抑制剂的组合产品
KR101464384B1 (ko) *	2005-11-22	2014-11-21	쿠도스 파마슈티칼스 리미티드	ｍＴＯＲ 억제제로서 피리도피리미딘, 피라조피리미딘 및피리미도피리미딘 유도체
JO2660B1 (en) *	2006-01-20	2012-06-17	نوفارتيس ايه جي	Pi-3 inhibitors and methods of use
EP1981890A2 (en) *	2006-01-25	2008-10-22	OSI Pharmaceuticals, Inc.	UNSATURATED mTOR INHIBITORS
WO2007120897A2 (en) *	2006-04-13	2007-10-25	The Trustees Of Columbia University In The City Of New York	Compositions and intraluminal devices for inhibiting vascular stenosis
CA2675558A1 (en) *	2007-02-06	2008-08-14	Novartis Ag	Pi 3-kinase inhibitors and methods of their use
RU2478387C2 (ru) *	2007-02-20	2013-04-10	Новартис Аг	ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
AU2008335469A1 (en) *	2007-12-13	2009-06-18	Novartis Ag	Combinations of therapeutic agents for treating cancer

2009
- 2009-10-29 CA CA2736361A patent/CA2736361C/en not_active Expired - Fee Related
- 2009-10-29 WO PCT/EP2009/064274 patent/WO2010049481A1/en not_active Ceased
- 2009-10-29 EP EP09744391.5A patent/EP2349275B1/en not_active Not-in-force
- 2009-10-29 RU RU2011121508/15A patent/RU2538683C2/ru not_active IP Right Cessation
- 2009-10-29 MX MX2011004585A patent/MX2011004585A/es active IP Right Grant
- 2009-10-29 BR BRPI0921802A patent/BRPI0921802A8/pt not_active IP Right Cessation
- 2009-10-29 CN CN201510402018.9A patent/CN105030784A/zh active Pending
- 2009-10-29 JP JP2011533721A patent/JP2012506898A/ja not_active Withdrawn
- 2009-10-29 CN CN2009801431736A patent/CN102202668A/zh active Pending
- 2009-10-29 KR KR1020117009771A patent/KR20110090911A/ko not_active Ceased
- 2009-10-29 AU AU2009309616A patent/AU2009309616B2/en not_active Ceased
- 2009-10-29 ES ES09744391.5T patent/ES2627677T3/es active Active
- 2009-10-29 US US13/123,956 patent/US20110195966A1/en not_active Abandoned
2014
- 2014-04-15 RU RU2014115188/15A patent/RU2014115188A/ru not_active Application Discontinuation
- 2014-09-05 JP JP2014181069A patent/JP2015013883A/ja not_active Withdrawn
2015
- 2015-11-24 US US14/950,869 patent/US20160136175A1/en not_active Abandoned
2016
- 2016-07-06 JP JP2016134514A patent/JP2017002058A/ja not_active Ceased
2018
- 2018-01-16 US US15/872,043 patent/US20180133226A1/en not_active Abandoned
- 2018-07-20 JP JP2018136756A patent/JP2018197243A/ja active Pending

Also Published As

Publication number	Publication date
CN105030784A (zh)	2015-11-11
JP2018197243A (ja)	2018-12-13
AU2009309616A2 (en)	2011-07-07
RU2538683C2 (ru)	2015-01-10
CA2736361C (en)	2017-10-10
WO2010049481A1 (en)	2010-05-06
EP2349275A1 (en)	2011-08-03
JP2012506898A (ja)	2012-03-22
MX2011004585A (es)	2011-06-01
AU2009309616A1 (en)	2010-05-06
JP2017002058A (ja)	2017-01-05
ES2627677T3 (es)	2017-07-31
BRPI0921802A8 (pt)	2018-03-13
RU2014115188A (ru)	2015-10-20
AU2009309616B2 (en)	2014-02-13
JP2015013883A (ja)	2015-01-22
US20160136175A1 (en)	2016-05-19
CA2736361A1 (en)	2010-05-06
KR20110090911A (ko)	2011-08-10
US20110195966A1 (en)	2011-08-11
US20180133226A1 (en)	2018-05-17
RU2011121508A (ru)	2012-12-10
CN102202668A (zh)	2011-09-28
EP2349275B1 (en)	2017-03-08

Legal Events

Date	Code	Title	Description
2018-04-17	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2018-04-24	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2020-11-10	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 11A ANUIDADE.
2021-03-02	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2601 DE 10-11-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
IL280173A (en)	2021-03-01	Inhibitors of brutons tyrosine kinase
BRPI0921156A2 (pt)	2016-02-23	inibidores de pi3k/mtor quinase
BRPI0910346A2 (pt)	2015-10-06	compostos de benzopirano e benzoxapina inibidores de pi3k e métodos de uso
HUS1900029I1 (hu)	2020-04-28	Kináz inhibitor foszforszármazékok
CY2017012I1 (el)	2017-11-14	Αναστολεις κινασης τυροσινης bruton
CR10369A (es)	2009-01-09	Pyrimidine derivatives as pi3k inhibitors
BRPI0915231A2 (pt)	2018-06-12	compostos inibidores de quinase e métodos de uso
DK2848610T3 (da)	2017-11-06	Hæmmere af kinaseaktivitet
BRPI0716781A2 (pt)	2014-11-18	Inibidores da quinase
BRPI1011129A2 (pt)	2016-11-01	métodos e compostos inibidores de janus cinase
BRPI0912294A2 (pt)	2015-10-20	compostos de triazina como inibidores de pi3 quinase e de mtor
NO20084665L (no)	2009-01-06	Quinazoliner for PDK1-inhibering
NO20084533L (no)	2009-01-09	Pyrimidin-derivat som PI3K-inhibitor og bruk av dette
DK2277509T3 (da)	2015-04-13	DPP IV inhibitorformuleringer
BR112012008483A2 (pt)	2019-09-24	combunações de um inibidor de pi3k e um inibidor de mex
EP2040546A4 (en)	2009-12-23	tyrosine kinase inhibitor
BRPI0717928A2 (pt)	2013-11-05	Imidazopiridazinas como inibidores da cinase de lipídio pi3k
EP2038272A4 (en)	2011-01-05	PYRIDINONYL-PDK1 INHIBITORS
SMP200800022B (it)	2008-04-02	Benzimidazoli sostituiti come inibitori delle chinasi
DK2402317T3 (da)	2013-10-07	DGAT-inhibitor
DK1986650T3 (da)	2012-08-13	Manipulationssikre doserignsformer
ATE506358T1 (de)	2011-05-15	2-benzylpyridazinonderivate als met-kinasehemmer
BRPI0922880A2 (pt)	2018-07-24	compostos inibidores de quinase
BRPI0907931A2 (pt)	2015-07-28	Derivado de pirrolopirimidina como inibidor de pi3k e uso do mesmo
DOP2007000082A (es)	2007-12-31	Inhibidores de quinasas de puntos de control